COVID: hydroxychloroquine trial in Detroit
A quasi-randomized trial of hydroxychloroquine in patients with COVID-associated pneumonia in Detroit, Michigan found worse outcomes with the med ( see covid hydroxychloroquine RTC nejm2020 in dropbox ). This study was just submitted to the New England Journal of Medicine, as a pre-publication and pre-peer reviewed submission Details: -- 63 consecutive adults with viral pneumonia, secondary to SARS-CoV-2 infection (documented by PCR) during a two-week period in March 2020 -- the trial was done in 2 different hospitals in Detroit, 7 miles apart, and serving the same general population -- 41% female (though 53% were on hydroxychloroquine/29% on standard care), baseline absolute lymphocyte count 0.92 K/ m L , baseline absolute neutrophil count 5.7 K/ m L, baseline respiratory support requirement 1.7 (statistically significant difference of 1.94 on hydroxychloroquine vs 1.52 on standard care,...